"Quinuclidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D011812
|
| MeSH Number(s) |
D03.605.687
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinuclidines".
Below are MeSH descriptors whose meaning is more specific than "Quinuclidines".
This graph shows the total number of publications written about "Quinuclidines" by people in this website by year, and whether "Quinuclidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 1 | 2 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quinuclidines" by people in Profiles.
-
Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Cancer Med. 2023 08; 12(15):15769-15776.
-
Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy. Adv Ther. 2023 07; 40(7):3217-3226.
-
Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. Future Oncol. 2021 Aug; 17(23):3027-3035.
-
Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. Oncologist. 2020 03; 25(3):e589-e597.
-
Nicotinic modulation of descending pain control circuitry. Pain. 2017 Oct; 158(10):1938-1950.
-
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochim Biophys Acta. 2015 Oct; 1848(10 Pt B):2738-46.
-
Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther. 2015; 9:155-61.
-
Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2014 Dec; 15(17):2599-608.
-
The current status of the use of palonosetron. Expert Opin Pharmacother. 2013 Jul; 14(10):1281-4.
-
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013 Jun; 21(6):1655-63.